🇺🇸 FDA
Patent

US 10550195

Tumor selective macropinocytosis-dependent rapidly internalizing antibodies

granted A61KA61K45/06A61K47/6801

Quick answer

US patent 10550195 (Tumor selective macropinocytosis-dependent rapidly internalizing antibodies) held by The Regents of the University of California expires Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Regents of the University of California
Grant date
Tue Feb 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 30 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K45/06, A61K47/6801, A61K47/6851, A61K47/6889